Stocks · News reference
JonesTrading Maintains Buy Rating and $82 Price Target for Rapport Therapeutics
JonesTrading analyst Justin Walsh has reaffirmed a 'Buy' rating and a $82 price target for Rapport Therapeutics, Inc. (NASDAQ: RAPP).
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Analysts Update Ratings and Price Targets for Rapport Therapeutics
Following the company's third-quarter earnings report, several financial institutions, including UBS and Guggenheim, adjusted their price targets for Rapport Therapeutics.
Guggenheim Maintains Buy on Rapport Therapeutics, Lowers Price Target to $66
Rapport Therapeutics Reports Third Quarter 2026 Financial Results and Business Update
Rapport Therapeutics announced its financial results for the third quarter of 2026, reporting a net loss of $40.2 million and providing updates on its clinical pipeline, including the RAP-219 program.
8-K filing — Rapport Therapeutics, Inc. (RAPP)
Filed: 2026-11-04 AccNo: 0001193125-26-446202 Size: 394 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Rapport Therapeutics Announces Participation in Upcoming Investor Conferences
Rapport Therapeutics announced that its management team will participate in the Stifel 2026 Healthcare Conference and the Jefferies Global Healthcare Conference in November 2026.